← SynDRA
ACALABRUTINIB
SynDRA canonical compound SYN0038494 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | BTK |
|---|
| Mechanism of action | Bruton's tyrosine kinase (BTK) inhibitor |
|---|
| Indication | mantle cell lymphoma (MCL) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- BTK
- BLK
- BMX
- EGFR
- ERBB2
- ERBB4
- GP6
- ITK
- JAK3
- LYN
- TEC
- TXK
Mechanisms of action (all sources)
- BTK INHIBITOR
- Tyrosine-protein kinase BTK inhibitor
- Bruton's tyrosine kinase (BTK) inhibitor
Drug classes
- Antineoplastic Agents
- Tyrosine Kinase Inhibitors
- Kinase Inhibitor
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- ACP-196
- calquence
- Calquence
- UNII-I42748ELQW
- I42748ELQW
- Acalabrutinib [INN]
- Acalabrutinib [USAN:INN]
- Calquence (TN)
- Acalabrutinib(ACP196)
- Acalabrutinib (ACP-196)
- GTPL8912
- Acalabrutinib (JAN/USAN/INN)
- SCHEMBL14637368
- EX-A881
- WDENQIQQYWYTPO-IBGZPJMESA-N
- KS-000006AT
- KS-000006AD
- s8116
- BDBM50175583
- AKOS030526094
- ZINC208774715
- DB11703
- CS-5356
- DS-3326
- ACP 196
- acalabrutinibum
- CHEBI:167707
- RefChem:57414
- L01XE51
- DTXCID401510462
- Bruton Tyrosine Kinase Inhibitor ACP-196
- MFCD29472294
- C26H23N7O2
- Acalabrutinib (Standard)
- ACP-196;Acalabrutinib
- ACALABRUTINIB [MI]
- ACALABRUTINIB [JAN]
- ACALABRUTINIB [USAN]
Look up ACALABRUTINIB in the interactive SynDRA portal →